Carlos L Arteaga

Carlos L Arteaga

UNVERIFIED PROFILE

Are you Carlos L Arteaga?   Register this Author

Register author
Carlos L Arteaga

Carlos L Arteaga

Publications by authors named "Carlos L Arteaga"

Are you Carlos L Arteaga?   Register this Author

100Publications

3446Reads

48Profile Views

Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?

JAMA Oncol 2019 Aug 29. Epub 2019 Aug 29.

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.2525DOI Listing
August 2019

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors.

Cancer Discov 2019 Apr 13;9(4):482-491. Epub 2019 Mar 13.

Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-1175DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445714PMC
April 2019

Author Correction: Drug response in organoids generated from frozen primary tumor tissues.

Sci Rep 2019 Apr 24;9(1):6517. Epub 2019 Apr 24.

Department of Biomedical Engineering, Vanderbilt University, Station B, Box 1631, Nashville, Tennessee, 37235, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-42133-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482154PMC
April 2019

Neratinib: Inching Up on the Cure Rate of HER2 Breast Cancer?

Clin Cancer Res 2018 08 25;24(15):3483-3485. Epub 2018 May 25.

Department of Medicine, UT Southwestern Medical Center, Dallas, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1114DOI Listing
August 2018

Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

Oncotarget 2018 08 17;9(64):32400. Epub 2018 Aug 17.

Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/26017
Publisher Site
http://dx.doi.org/10.18632/oncotarget.26017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122353PMC
August 2018

TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association.

BMC Cancer 2018 Jun 19;18(1):670. Epub 2018 Jun 19.

Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York, 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4587-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008941PMC
June 2018

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.

J Natl Cancer Inst 2017 11;109(11)

Department of Medicine and Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN; Department of Cancer Biology, Vanderbilt University, Nashville, TN; Symphogen, Ballerup, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543617PMC
November 2017

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.

Cell Metab 2017 Oct;26(4):633-647.e7

Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmet.2017.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650077PMC
October 2017

Neoadjuvant Trials in ER Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.

Cancer Discov 2017 06 11;7(6):561-574. Epub 2017 May 11.

Departments of Medicine and Cancer Biology; Breast Cancer Program, Vanderbilt-Ingram Cancer Center; Vanderbilt University Medical Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-0228DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497752PMC
June 2017

Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA in HER2/ER-positive breast cancer.

Breast Cancer Res Treat 2016 12 22;160(3):457-474. Epub 2016 Oct 22.

Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, 37203, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-016-4011-9
Publisher Site
http://dx.doi.org/10.1007/s10549-016-4011-9DOI Listing
December 2016

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.

Cancer Metastasis Rev 2016 12;35(4):515-524

Departments of Medicine and Cancer Biology; Breast Cancer Program, Vanderbilt-Ingram, Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-016-9637-xDOI Listing
December 2016

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2016 11 7;375(18):1738-1748. Epub 2016 Oct 7.

From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609709DOI Listing
November 2016

The PI3K/AKT Pathway as a Target for Cancer Treatment.

Annu Rev Med 2016 14;67:11-28. Epub 2015 Oct 14.

Departments of Medicine and Cancer Biology; Breast Cancer Program, Vanderbilt-Ingram Cancer Center; Vanderbilt University School of Medicine, Nashville, Tennessee 37232; email: ,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-062913-051343DOI Listing
October 2016

Is There a Future for AKT Inhibitors in the Treatment of Cancer?

Clin Cancer Res 2016 06 15;22(11):2599-601. Epub 2016 Mar 15.

Breast Cancer Program, Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891224PMC
June 2016

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

Sci Transl Med 2016 Apr;8(334):334ra53

Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA. Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA. Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aad3001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256931PMC
April 2016

Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.

Mol Cell Proteomics 2016 Feb 9;15(2):642-56. Epub 2015 Dec 9.

From the ‡Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee 37203; ‖Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232; **Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232; ¶¶School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas 77030

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/mcp.M115.053199DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739678PMC
February 2016

Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

Cancer Res 2016 Jan 16;76(2):440-52. Epub 2015 Dec 16.

Department of Medicine, Vanderbilt University, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee. Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-1640-TDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715956PMC
January 2016

Drug response in organoids generated from frozen primary tumor tissues.

Sci Rep 2016 Jan 7;6:18889. Epub 2016 Jan 7.

Department of Biomedical Engineering, Vanderbilt University, Station B, Box 1631, Nashville, Tennessee, 37235, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep18889DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703961PMC
January 2016

Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.

Breast Cancer Res 2015 Dec 4;17:148. Epub 2015 Dec 4.

Department of Cancer Biology, Vanderbilt University, 2220 Pierce Avenue, Nashville, TN, 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-015-0656-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670529PMC
December 2015

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

Circulation 2015 Dec;132(23):2248-58

From Department of Medicine, Brigham and Women's Hospital, Boston, MA (A.M.B., G.D.D.); Vanderbilt-Ingram Cancer Center (C.L.A., J.M.), Cardiovascular Division (T.F., J.J.M.), and Cardio-Oncology Program (C.L.A., T.F., J.J.M.), Vanderbilt University School of Medicine, Nashville, TN; Department of Medicine, Washington University Medical Center, St. Louis, MO (B.D.H., J.M.); Dana-Farber Cancer Institute and Ludwig Center at Harvard, Harvard Medical School, Boston, MA (G.D.D.); and Knight Cancer Institute, Oregon Health & Science University and Howard Hughes Medical Institute, Portland, OR (B.J.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.115.010484DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863699PMC
December 2015

HER2 missense mutations have distinct effects on oncogenic signaling and migration.

Proc Natl Acad Sci U S A 2015 Nov 27;112(45):E6205-14. Epub 2015 Oct 27.

Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1516853112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653184PMC
November 2015

Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy.

Cancer Discov 2015 Nov;5(11):1124-6

Center for Cancer Targeted Therapies, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee. Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-1166DOI Listing
November 2015

NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.

J Natl Compr Canc Netw 2015 Nov;13(11):1337-46

From UC San Diego Moores Cancer Center, San Diego, California; Stanford Cancer Institute, Stanford, California; Fox Chase Cancer Center, Philadelphia, Pennsylvania; Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, Ohio; Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Washington University, St. Louis, Missouri; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; City of Hope Comprehensive Cancer Center, Los Angeles, California; The West Clinic, Memphis, Tennessee; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California; Johns Hopkins University School of Medicine, Baltimore, Maryland; and Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0163DOI Listing
November 2015

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

J Clin Oncol 2015 Aug 13;33(24):2623-31. Epub 2015 Jul 13.

Nancy U. Lin, Hao Guo, Nicole Ryabin, Julie S. Najita, William T. Barry, Ian E. Krop, Eric P. Winer, and Annick D. Van den Abbeele, Dana-Farber Cancer Institute; Andrea L. Richardson and Annick D. Van den Abbeele, Brigham and Women's Hospital, Boston, MA; Jeffrey T. Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Ingrid A. Mayer and Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN; Carla I. Falkson, University of Alabama, Birmingham, AL; Timothy J. Hobday, Mayo Clinic, Rochester, MN; E. Claire Dees, University of North Carolina, Chapel Hill, NC; Rita Nanda, University of Chicago, Chicago, IL; Mothaffar F. Rimawi, Baylor College of Medicine, Houston, TX; and Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534525PMC
August 2015

Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics.

Acad Radiol 2015 Jun 18;22(6):779-86. Epub 2015 Mar 18.

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2015.01.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429002PMC
June 2015

Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts.

J Biomed Opt 2015 Feb;20(2):26004

Vanderbilt University, Department of Biomedical Engineering Station B, Box 1631, Nashville, Tennessee 37235, United States.

View Article

Download full-text PDF

Source
http://biomedicaloptics.spiedigitallibrary.org/article.aspx?
Publisher Site
http://dx.doi.org/10.1117/1.JBO.20.2.026004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335617PMC
February 2015

Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Cancer Res 2015 Jan 5;75(2):405-14. Epub 2014 Dec 5.

Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-2475DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297507PMC
January 2015

PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.

Hematol Oncol Stem Cell Ther 2014 Dec 29;7(4):142-8. Epub 2014 Oct 29.

Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hemonc.2014.09.007DOI Listing
December 2014

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.

Oncotarget 2014 Oct;5(19):9049-64

Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX. Systems Biology, The University of Texas, MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253418PMC
http://dx.doi.org/10.18632/oncotarget.2022DOI Listing
October 2014

In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.

Biomed Opt Express 2014 Jul 16;5(7):2247-61. Epub 2014 Jun 16.

Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1364/BOE.5.002247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102362PMC
July 2014

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

J Clin Oncol 2014 Apr 24;32(12):1202-9. Epub 2014 Mar 24.

Ingrid A. Mayer, Vandana G. Abramson, Justin M. Balko, María Gabriela Kuba, Melinda E. Sanders, and Carlos L. Arteaga, Vanderbilt University, Nashville, TN; Steven J. Isakoff, Massachusetts General Hospital, Boston, MA; Andres Forero, University of Alabama, Birmingham, AL; Jeffrey T. Yap, Huntsman Cancer Institute, Salt Lake City, UT; Annick D. Van den Abbeele and Eric Winer, Dana-Farber Cancer Institute, Boston, MA; Yisheng Li, MD Anderson Cancer Center, Houston, TX; and Lewis C. Cantley, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/03/18/JCO.2013.54
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.0518
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.0518DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986383PMC
April 2014

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

Cancer Cell 2014 Mar;25(3):282-303

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.02.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018830PMC
March 2014

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

Cancer Discov 2014 Feb 19;4(2):232-45. Epub 2013 Dec 19.

Departments of 1Medicine, 2Pathology, Microbiology & Immunology, 3Cancer Biology, and 4Biochemistry; 5Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; Departments of 6Cell & Tissue Biology and 7Medicine, University of California, San Francisco, San Francisco, California; 8Foundation Medicine, Cambridge, Massachusetts; 9Oncosalud; and 10Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Perú

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0286DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946308PMC
February 2014

Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy.

J Biomed Opt 2014 Feb;19(2):025001

Vanderbilt University, Department of Biomedical Engineering, VU Station B #351631, 2301 Vanderbilt Place, Nashville, Tennessee 37235.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1117/1.JBO.19.2.025001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913568PMC
February 2014

Heart failure and breast cancer therapies: moving towards personalized risk assessment.

J Am Heart Assoc 2014 Feb 28;3(1):e000780. Epub 2014 Feb 28.

Cardio-Oncology Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/JAHA.113.000780DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959702PMC
February 2014